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Abstract
Background: Osteopontin (OPN) is associated with human cancers, and circulating blood OPN
may have diagnostic or prognostic value in clinical oncology.
Methods: To evaluate OPN as a cancer biomarker, we generated and characterized five novel
mouse monoclonal antibodies against the human full-length OPN (fl-OPN). Epitopes recognized by
four antibodies (2C5, 2F10, 2H9, and 2E11) map to N-terminal OPN (aa1-166); one (1F11) maps
to C-terminal OPN (aa167-314). These antibodies recognize recombinant and native OPN by
ELISA and immunoblot, cross reacting with human and mouse OPN. Two of these novel antibodies
(2F10 and 1F11) were used to develop a quantitative enzyme linked immunosorbent assay (ELISA)
for fl-OPN.
Results: In comparison with commercially available ELISAs, our assay had high accuracy in
measuring fl-OPN standards, and high sensitivity. Specifically, our ELISA has a linear dose response
between 0.078 ng/ml-10 ng/ml, with a sensitivity of 13.9 pg/ml. We utilized this assay to quantify fl-
OPN in the plasma of healthy volunteers in comparison with patients with metastatic breast cancer.
The average circulating plasma fl-OPN in healthy volunteers was 1.2 ng/ml, compared to 4.76 ng/
ml in patients with metastatic breast cancer (p = 0.0042). Although the increase in fl-OPN in cancer
patients is consistent with previous studies, the measured quantity varied greatly between all
existing fl-OPN ELISAs.
Conclusion: Because OPN is a complex molecule with diversity from alternative splicing, post-
translational modification, extracellular proteolytic modification, and participation in protein
complexes, we suggest that further understanding of specific isoform recognition of multiple OPN
species is essential for future studies of OPN biomarker utility.
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Osteopontin (OPN) is a secreted phosphorylated glyco-
protein that was originally isolated from bone and con-
trols biomineralization, osteoclast differentiation, and
bone resorption [1]. Recent literature has linked up-regu-
lated expression of osteopontin with cancer, atherosclero-
sis, bone remodeling, angiogenesis, wound healing and
tissue injuries, as well as certain pathologies such as reste-
nosis, formation of kidney stones, and autoimmune dis-
ease [2-7]. OPN belongs to the SIBLING (Small integrin
binding ligand N-linked glycoprotein) protein family,
and binds receptors including integrins and CD44.
OPN is of high interest in human cancer, and is expressed
in malignancies of various tissue origins [8,9]. Since OPN
is a secreted molecule that is found in the circulation and
in bodily fluids, it has been explored as a potential non-
invasive biomarker for the diagnosis or progression of
cancer. Early studies of OPN identified it as a highly phos-
phorylated protein associated with advanced-stage can-
cers [10,11] that was found as lower molecular weight
fragments in human serum, suggesting proteolysis by
enzymes related to the coagulation cascade. Several stud-
ies have used enzyme-linked immunosorbent assays
(ELISA) as a method to quantify circulating blood OPN
levels in cancer patients. While the studies yielded varia-
ble conclusions, levels of circulating plasma OPN may be
a biomarker of ovarian cancer [12], as there was a trend
for decreased OPN levels following treatment of ovarian
cancer, and levels rose early in patients with recurrent dis-
ease [13]. High levels of OPN were also present in the
blood of patients with lung carcinoma [14], hepatocarci-
noma [15], metastatic prostate carcinoma [16], and meta-
static breast cancer [17], compared to healthy volunteers.
Levels of circulating OPN have also been studied as a
prognostic factor, and high OPN levels are associated with
poor prognosis in esophageal carcinoma [18], head and
neck squamous cell carcinoma [19], and breast cancer
[20].
ELISA quantification of blood OPN has been accom-
plished using commercially available assays from IBL and
Assay Designs. One recent study directly compared these
assays to quantify plasma OPN from patients with head
and neck cancer or cervical cancer. The quantification of
the same samples were positively correlated, although the
absolute values were significantly different, suggesting
that assay accuracy is a challenge [21]. There is also an
ELISA test from R&D Systems (Quantikine) available
commercially. We have developed and characterized a
novel ELISA detecting full-length OPN from human
plasma, and find a greater sensitivity to low OPN concen-
trations in our assay compared to the existing assays.
However, our ELISA also varies in absolute values with the
IBL and Assay Designs OPN ELISAs, although our results
were more accurate, along with the R&D ELISA, in meas-
urement of commercially available OPN protein stand-
ards. Our quantification of OPN levels in plasma from
healthy individuals versus those with metastatic breast
cancer patients showed an elevated level among those
with breast cancer. Of interest, our results also demon-
strated significantly different absolute values (ng/ml) in
both populations compared to previously published liter-
ature. We conclude that existing assays for measurement
of OPN in human blood have not been independently
validated, and that there may be complications in quanti-
fication of OPN from complex samples, possibly due to
interacting proteins found in human plasma that may
affect accurate OPN quantification.
Methods
OPN protein and monoclonal antibody production
Recombinant human full-length OPN (fl-OPN), human
N-OPN and human C-OPN fragments representing the
MMP cleaved products were produced in E. coli, and puri-
fied as previously described [22]. OPN trilevel controls
were purchased from R&D systems. This recombinant
full-length OPN has a C-terminal 6x-His tag and was
expressed in NS0 mouse myeloma cells. The ranges given
for these controls are 1.66–2.26 ng/ml, 5.03–6.57 ng/ml,
10.13–13.09 ng/ml. Native OPN purified from human
milk [23] was a generous gift of Esben Sørensen (Univer-
sity of Aarhus, Denmark). All animal protocols were
reviewed and approved by our Institutional Animal Use
and Care Committee, and performed under veterinary
supervision. The fl-OPN protein was used for immuniza-
tion of OPN homozygous null mice [24]. Prior to immu-
nization, pre-immune blood was collected from mice by
retro-orbital bleed. Antibody generation was accom-
plished by subcutaneous injection of 100 μg fl-OPN in
Complete Freund's adjuvent (Sigma, F5881), followed by
subsequent injections of 50 μg fl-OPN in Incomplete Fre-
und's Adjuvent (Sigma F5506) on days 13, 33, 45, and
161 days after the initial injection. The mice were then
bled and antibody titer measured by ELISA. Final injec-
tions of 30 μg fl-OPN intraperitoneally/20 μg fl-OPN sub-
cutaneously were given 4 days before collection of the
spleen for fusion. The hybridomas were generated by fus-
ing splenocytes with FO myeloma cells of Balb/c origin
(ATCC, Manassas, VA), according to a standard protocol
developed by Kohler and Milstein (Kohler G, Milstein, C,
1975), with minor modifications.
Enzyme-linked immunosorbent assay (ELISA)
After five rounds of immunization, 0.1 ml blood was col-
lected by retro-orbital bleed to determine the OPN anti-
body level in the serum. A 96-well microtiter plate (BD
Biosciences, Bedford, MA.) was coated with 50 ng/ml
(100 μl/well) of purified human fl-OPN and incubated at
4°C overnight. The plate was blocked with 3% nonfat dryPage 2 of 11
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temperature for 2 hours. The sample serum was loaded at
a 1:100 dilution in 3% nonfat dry milk/PBS-T, followed
by serial 5-fold dilutions. After incubation at 37°C for 1
hour, the plate was washed with PBS-T, and incubated at
37°C for 2 hours with a combination of two separate sec-
ondary antibodies at 100 μl/well: 1:5000 dilution of HRP-
conjugated goat anti-mouse IgG, Fcγ fragment specific,
and a 1:5000 dilution of HRP-conjugated AffiniPure goat
anti-mouse IgG + IgM (H+L) (both from Jackson Immu-
noResearch Laboratories). Antigen was detected by incu-
bation with 100 μl/well of tetramethylbenzidine for 15
minutes, and the reaction was stopped by 100 μl/well of
1 M HCl. The plate was read at 405 nm using an auto-
mated microplate reader (Bio-Tek Instruments). Screen-
ing of subsequent hybridomas was performed similarly,
with HRP-conjugated goat antimouse IgG + IgM used as
the secondary antibody. In addition, hybridoma screen-
ing included negative selection of clones that recognized
an unrelated control his-tagged protein, and positive
selection of clones recognizing a second recombinant
OPN without a his epitope tag. For crossreactivity studies,
wells were coated with either human or mouse fl-OPN,
and human N- and Cterminal OPN fragments were used
for epitope mapping. To compare epitope specificity,
unlabeled anti-OPN antibodies were used to compete
with biotinylated 1F11 and 2F10 for binding to specific
OPN epitopes. Unlabeled antibodies were incubated first,
followed by reaction with the biotinylated antibodies to
detect binding.
Production of ascites fluid and antibody purification
Ascites fluid was collected using either Hsd athymic nude
mice or F1 hybrids (H-2b/d MHC class) of OPN hetero-
zygous mice (C57BL/6 H-2b) crossed to Balb/c mice (H-
2d). Mice were primed with an intraperitoneal injection of
incomplete Freund's adjuvant, followed by injection of 5
× 105 – 5 × 106 hybridoma cells. Ascites was collected from
peritoneal tapping. For antibody purification, ascites were
centrifuged at 14,000 g for 15 minutes and diluted with 5
volumes of 20 mM sodium phosphate buffer, pH = 7.0.
Antibodies were purified over a protein G column
(Sigma), and eluted with 0.1 M glycine-HCl, pH = 2.7 and
adjusted to neutral pH with 1 M Tris-HCl, pH = 8. Eluted
antibodies were dialyzed against PBS. Antibody concen-
tration was determined with a DC protein assay kit (Bio-
Rad). On average, 1–4 mg antibody was purified from 1
ml ascites fluid. Purity of antibodies was assessed by SDS-
PAGE and Coomassie blue staining. Antibody isotypes
were determined using the IsoStrip assay (Roche) follow-
ing the manufacturer's instructions.
Antibody biotinylation
Sulfo-NHS-LC-Biotin [sulfosuccinimidyl-6-(biotina-
mido) hexanoate] (MW 556.59, Pierce) was prepared at
10 mg/ml in PBS and added to dialyzed MAbs 1F11, 2F10,
and 1E3 at a ratio of 186 μg, 148 μg and 150 μg of biotin
per mg of antibody, respectively. IE3, a monoclonal anti-
body against platelet activation antigen CD62-P was used
as a control [25]. The mixtures were incubated at room
temperature for 1 hour before being dialyzed extensively
against PBS to remove uncoupled biotin. The quantities of
the biotinylated proteins were then determined using a
DC protein assay kit (Bio-Rad).
Sandwich ELISA
A two-antibody sandwich ELISA was developed as a quan-
titative ELISA for fl-OPN measurement. MAb 2F10, which
binds specifically to the N-terminus of OPN, was selected
as the capture antibody; while 1F11, specific for the C-ter-
minus, was selected as the detection antibody (1F11 was
biotinylated). This assay design aimed to detect only OPN
molecules that were intact and not cleaved. Firstly, chess-
board titrations were performed with 2F10 as the capture
antibody and 1F11b as the detecting antibody and fl-OPN
as the antigen. The chessboard showed that a dilution of
1.5625 μg/ml of 2F10 and 0.0975 μg/ml of 1F11b would
be the optimal concentrations for the sandwich ELISA.
The capture antibody, 2F10, was then used at a concentra-
tion of 1.5625 μg/ml in PBS pH = 8.0 and coated at 100
μl/well overnight at 4°C. PMSF (1 mM) and protease
inhibitor cocktail (Sigma, 0.5 μl/ml) were added to the
blocking and carrying solution of 1% BSA/PBS (referred
to hereafter as 1%BSA/PBS/PIC). Wells were blocked with
1%BSA/PBS/PIC for 2 hours at room temperature on a
plate shaker at ~500 rpm, washed, and samples and stand-
ards loaded for 1 hour at room temperature. After wash-
ing, the biotinylated detecting antibody, 1F11b, was
added at 0.0975 μg/ml in 1%BSA/PBS/PIC and incubated
for 1 hour. After washing, 1:2000 HRPconjugated strepta-
vidin (Jackson Immunoresearch) was incubated for 1
hour, followed by washing and antigen detection with
tetramethylbenzidine (TMB). The chromogenic reaction
was stopped with 1 M HCl and the plate read at 405 nm
with a correction at 570 nm.
Plasma collection
Our Institutional Review Board evaluated and approved
the protocols for the use of healthy volunteer and patient
samples. Plasma samples were collected from 55 healthy
blood donors as well as 40 women with metastatic breast
cancer (Dr. Susan Miesfeldt, Maine Center for Cancer
Medicine and Blood Disorders, Scarborough, Maine). All
samples were collected in EDTA tubes; the plasma was
then separated, aliquoted into 200 μl and frozen at -70°C
within 4 hours of collection. Data on initial stage, histol-
ogy, receptor status, and disease free interval are presented
in the text.Page 3 of 11
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Sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) was performed with a Mini-PROTEAN
Gel Electrophoresis Unit (Bio-Rad). Protein samples were
diluted appropriately and boiled for 5 minutes in the sam-
ple buffer (63 mM Tris, 2% SDS, 0.01% bromophenol
blue, 5% β-mercaptoethanol). The resolving gel was
12.5% and the stacking gel was 5%. The running buffer
consisted of 25 mM Tris base, 192 mM glycine, 0.1% SDS,
pH = 8.8. The separated proteins on the gel were trans-
ferred to a polyvinylidene diflouride (PVDF) membrane
with the Mini-PROTEAN Gel Electrophoresis unit (Bio-
Rad Laboratories) The transfer buffer consisted of 25 mM
Tris, 192 mM glycine and 0.1% SDS, pH = 8.3.
Nonspecific binding was blocked with 3% BSA in TBS-T
buffer (10 mM Tris, pH = 8.0, 150 mM NaCl,
0.05%Tween-20) at room temperature for 1 hour. The
membrane was then cut into strips and incubated in indi-
vidual tubes with the appropriate dilution of the MAbs in
3% BSA in TBST buffer overnight. After the overnight
incubation at 4°C the strips were washed in TBS-T in their
own tubes for 1.5 hours. The strips were incubated with
3% BSA for 30 minutes, washed 3X in TBS-T, and incu-
bated with HRP-conjugated goat anti-mouse IgG, Fcγ
(1:10,000) in 3% BSA TBS-T for 1 hour, followed by a
TBS-T and 3% BSA washes. The bands were visualized
using an ECL Western blotting detection reagent (Amer-
sham). Prestained molecular weight standards (Bio-Rad)
were used to estimate protein sizes.
Results
Characterization of anti-OPN monoclonal antibodies
Monoclonal antibodies (MAb) recognizing human fl-
OPN were purified and characterized, and included MAb
2C5, 2H9, 2F10, 2E11 and 1F11. Antibodies were origi-
nally identified by their recognition of fl-OPN by ELISA.
All are of the IgG1 subtype, with a κ light chain. During
the course of the screening, these antibodies were found
not to cross react with a random hiscontaining protein,
and also recognize a recombinant OPN lacking a his
epitope tag. Using human or mouse recombinant fl-OPN
protein, we found that under denaturing, reduced condi-
tions, all MAb recognized the recombinant proteins,
although the detection of human OPN was more robust
(Fig. 1A). OPN is known to run anomalously by SDS-
PAGE (~50–70 kD), not corresponding to its actual
molecular mass (~35 kD). Antibody recognition to the
OPN molecule was mapped to either an N-terminal or C-
terminal epitope by ELISA, using purified recombinant
protein (Fig. 1B). Epitopes of MAb 2C5, 2F10, 2H9, and
2E11 map to the human N-terminal fragment (aa1-
aa166), while that of 1F11 maps to the C-terminal frag-
ment (aa167-aa314). This was verified by immunoblot
analysis using the same recombinant N-terminal or C-ter-
minal OPN fragment (Fig. 1C).
The antibodies were then tested for recognition of native
OPN protein by ELISA and immunoblot analysis. We
obtained purified native human milk OPN [23] and
tested activity of the MAb by ELISA (Fig. 2A). MAb 1F11
Characterization of anti-OPN MAbFigure 1
Characterization of anti-OPN MAb. All Mab were screened based on their ELISA detection of full-length human OPN (fl-
OPN). A) Recombinant human or mouse fl-OPN were used for immunoblot with the anti-OPN MAb indicated. Each lane was 
loaded with 20 ng OPN protein for detection. While the recognition of human OPN was greater by all MAb, they all cross-
reacted with murine OPN. B) An ELISA was performed using the human N-terminal (aa-1-167) or C-terminal (aa167-314) 
human recombinant fragments. Each lane was loaded with 250 ng protein. MAb 1E3 is an irrelevant antibody used as a negative 
control. 2C5, 2H9, 2F10, and 2E11 recognize OPN epitopes on the N-terminal fragment, while 1F11 recognizes an epitope on 
the C-terminal fragment. C) The same OPN fragments were tested by immunoblot, and yielded consistent results with the 
ELISA.Page 4 of 11
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quantitative sandwich ELISA, both recognized human
native milk OPN. We also collected mouse kidneys, which
are tissues known to contain endogenous OPN protein
[26,27]. We tested wild kidneys from wild type, OPN het-
erozygous, and OPN null mice [24], compared to recom-
binant human OPN (Fig. 2B). OPN was detected in
kidneys from wild type and OPN heterozygous mice, but
not from kidneys from OPN null animals, showing recog-
nition of mouse native OPN. Finally, since OPN expres-
sion in smooth muscle cells is induced by Notch signaling
[28], we also tested human aortic smooth muscle cells
with activated Notch, and found strong expression of
OPN detectable by both 1F11 and 2F10 MAb. These data
support the specificity of the antibody in recognition of
native mouse and human OPN protein.
Development of OPN quantitative enzyme-linked 
immunosorbent assay (ELISA)
MAb 2F10 specific for the N-terminus of OPN and MAb
1F11 specific for the C- terminus were evaluated as a cap-
ture-detection antibody pair in a sandwich ELISA for OPN
quantification. To aid detection of signals, the detection
antibody was biotinylated. 2F10 was designated the cap-
ture antibody, and biotinylated 1F11 was the detection
antibody. This antibody selection ensured that only rela-
tively intact OPN molecules would be recognized and
quantitatively determined. Chessboard reagent titration
experiments were carried out to define optimal assay
parameters. Based on this analysis (Table 1) using excess
antigen, we found that absorbance plateaued from 50 μg/
ml to 3.125 μg/ml of capture antibody, with the drop
occurring using 0.78 μg/ml. Thus, we determined the opti-
mal capture antibody concentration as 1.56 μg/ml. In the
second checkerboard assay, 1.56 μg/ml was used as the
coating concentration with a serial dilution of fl-OPN
from 0.156 μg/ml to 2.4 pg/ml, with no fl-OPN as a neg-
ative control. From columns 1–11 a serial dilution of
detecting antibody was used from 1.56 μg/ml to 1.5 ng/
ml, with no detecting antibody in column 12. At 9.7 ng/
ml of fl-OPN, the absorbance plateaued between 1.56 μg/
ml of 1F11b to 0.195 μg/ml, with a drop occurring at
0.098 μg/ml. A titration of the fl-OPN antigen occurs
using 0.098 μg/ml 1F11b between 19.5 ng/ml of Fl-OPN
to 2.4 pg/ml. Thus, the capture antibody optimum con-
centration is 1.56 μg/ml while the detecting antibody
1F11b optimum concentration is 0.0975 μg/ml.
A sandwich ELISA was developed using MAb 2F10 (N-ter-
minal OPN specific) as capture antibody and biotinylated
1F11 (C-terminal OPN specific) as detection antibody.
This ELISA permits quantitative, rapid and reproducible
measurement of OPN levels in blood plasma and other
bodily fluids. The fl-OPN was used as antigen in this assay
to generate the standard curve for calculating OPN con-
centration of unknown samples. The resulting standard
curve had a linear correlation (R2>0.99, Fig. 3A) between
OPN concentration and A405nm, with a linear dosere-
sponse range of 0.078 ng/ml-10 ng/ml. Thus, the sand-
wich ELISA generates a standard curve that can be used to
provide accurate determinations of fl-OPN concentra-
tions in test samples. The assay protocol was followed
subsequently to measure OPN level in test samples. Assay
sensitivity was calculated by comparing binding with no
fl-OPN compared to 0.156 ng/ml. The detection limit was
determined as the concentration of human OPN meas-
Recognition of native OPN by anti-OPN MAbFigure 2
Recognition of native OPN by anti-OPN MAb. A) Human milk OPN was used in ELISA, and 1F11 and 2F10 binding com-
pared to an irrelevant antibody (MAb 1E3, control). B) Whole kidney lysates were collected from wild type (WT) mice, OPN 
heterozygous mice (Het), and OPN null mutant mice (Null). Lysates were loaded equally and analyzed by SDS-PAGE followed 
by immunoblotting using 1F11. Recombinant OPN was used as a control. C) Human aortic smooth muscle cells (SMC) were 
transduced with activated Notch1 receptor [41] to increase OPN expression, and compared to human umbilical vein endothe-
lial cells (EC). Both 2F10 and 1F11 recognize OPN in SMC.Page 5 of 11
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along the curve. The mean OD for the control was 0.049
± 0.0017, and the mean OD at 0.156 ng/ml was 0.087 ±
0.0025, giving a deltaOD = 0.038. Our calculations
yielded a sensitivity of 13.9 pg/ml.
Table 1: Chessboard titrations of ELISA antibodies
2F10 μg/ml
fl-OPN 50 25 12.5 6.25 3.125 1.56 0.781 0.39 0.20 0.098 0.049 0
5 2.66 2.73 2.92 3.32 3.66 3.78 1.30 0.76 0.54 0.43 0.459 0.332
2.5 2.84 o.s. 3.07 o.s. o.s. 3.89 1.16 0.60 0.40 0.29 0.276 0.18
1.25 2.62 o.s. o.s. 3.44 o.s. 3.95 1.14 0.49 0.32 0.20 0.174 0.119
0.625 2.74 o.s. o.s. o.s. o.s. o.s. 1.17 0.34 0.24 0.17 0.154 0.086
0.313 2.86 o.s. o.s. o.s. o.s. o.s. 1.01 0.31 0.20 0.15 0.126 0.074
0.156 o.s. o.s. o.s. o.s. o.s. o.s. 0.964 0.322 0.184 0.106 0.076 0.054
0.078 o.s. o.s. o.s. o.s. o.s. o.s. 0.971 0.304 0.182 0.102 0.076 0.05
0 1.619 1.869 1.071 0.523 0.285 0.177 0.119 0.084 0.073 0.071 0.069 0.071
1F11b μg/ml
fl-OPN 1.56 0.78 0.39 0.195 0.098 0.049 0.024 0.012 0.006 0.003 0.0015 0
0.156 3.66 3.80 3.801 3.77 3.74 3.61 2.16 1.473 0.77 0.41 0.254 0.041
0.078 3.83 o.s. o.s. 3.93 o.s. 3.31 1.91 1.06 0.62 0.37 0.231 0.041
0.039 3.83 o.s. o.s. o.s. 3.96 3.07 2.36 1.047 0.56 0.32 0.185 0.035
0.020 3.84 o.s. o.s. o.s. 3.76 2.43 1.41 0.763 0.41 0.24 0.154 0.039
0.0098 3.86 o.s. 3.48 3.49 2.45 1.61 0.95 0.643 0.34 0.20 0.132 0.039
0.0049 3.82 3.81 2.79 2.27 1.53 0.96 0.50 0.358 0.22 0.16 0.142 0.036
0.002 3.05 2.40 1.54 1.18 0.90 0.60 0.32 0.215 0.13 0.087 0.07 0.04
0 0.46 0.26 0.17 0.10 0.069 0.05 0.05 0.04 0.03 0.04 0.038 0.038
Both the capture antibody (2F10, top) and the detecting antibody (1F11, bottom) were analyzed for dose response in a checkerboard analysis. The 
optimal concentrations (bold) are 1.56 μg/ml capture antibody and 0.098 μg/ml detecting antibody 1F11b. Conditions listed as o.s. (off-scale) had an 
absorbance > 4.0.
Comparison of OPN ELISA testsFigure 3
Comparison of OPN ELISA tests. A) Our assay was tested for quantification of recombinant fl-OPN using monoclonal 
antibodies 2F10 and 1F11-biotin. 2F10 reacts to an epitope on the N-terminal of human OPN and 1F11-biotin reacts with an 
epitope on the C-terminal side of human OPN. The optical density of the color product is proportional to the quantity of 
human OPN. The measuring range is from 78 pg/ml to 10 ng/ml. B) Commercially prepared human OPN standards of high 
(10.1 ng/ml-13.1 ng/ml), medium (5 ng/ml-6.6 ng/ml) or low (1.7 ng/ml-2.3 ng/ml) concentrations were used in four ELISA tests: 
our in-house test, and those commercially available from Assay Designs, R&D Systems (Quantikine) and IBL. The IBL results 
are graphed separately because the IBL quantification yielded values that were extremely high compared to the other assays 
and the standard ranges.Page 6 of 11
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Currently there are three fl-OPN kits on the market (IBL,
Assay Designs, R&D Systems) used previously to quantify
plasma OPN levels in cancer patients. Thus, we compared
our ELISA with the commercially available tests. The
detection limits of these assays are: IBL, 5–320 ng/ml;
Assay Designs, 2–32 ng/ml; Quantikine R&D, 0.312–20
ng/ml. We obtained fl-OPN control proteins from R&D
Systems representing a high (10.1–13.1 ng/ml), middle
(5–6.6 ng/ml), and low (1.7–2.3 ng/ml) protein concen-
tration, and compared assay results using these standards
(Fig. 3B). The quantification of fl-OPN varied in all assays,
and we compared the actual values with the known stand-
ards, as well as the relationship between the three stand-
ards, which represent a twofold (1:2) and three fold (1:3)
decrease from the high and the middle standards, respec-
tively. Our in-house assay and the Quantikine R&D ELISA
were the most accurate, while the Assay Designs over-esti-
mated the standard values from 1.2-fold to 3.6 fold. The
relationship between the standards from highest to lowest
(1:2/1:3) was proportionally consistent with the in-house
(1:2/1:3.1) and Quantikine R&D (1:1.8/1:3.1) assays, but
not with the Assay Designs kit (1:1.6/1:1.3). The IBL
ELISA kit gave extremely high measurements for these
same standards, running 13-fold to 18-fold higher than
the standard ranges. The relationship between the high
and middle standards was measured as expected with the
IBL assay (1:1.8), however, was not consistent between
the middle and low standard (1:4).
Measurement of OPN in Plasma Samples
In an initial attempt to evaluate OPN as a biomarker for
cancer, the quantitative ELISA was used to measure fl-
OPN levels in patients with metastatic breast cancer
(Table 2). In addition, because the available fl-OPN assays
were so variable, we compared our results to those using
the commercially available kits. The patient population
with metastatic breast cancer was chosen for testing, since
similar populations have previously been studied with the
commercially available OPN ELISAs, and provide a basis
for comparison. Using our in-house assay, we initially
compared fl-OPN levels in fifty-one healthy controls with
levels from forty metastatic breast cancer patients (Fig.
4A). The plasma fl-OPN level among control subjects
averaged 1.22 ± 0.446 ng/ml, while the average level in
breast cancer samples was 4.76 ± 1.233 ng/ml (p =
0.0042).
We then compared our results of fl-OPN quantification in
the plasma of normal volunteers or breast cancer patients
with the commercially available assays. In all cases, the
standard curves were linear, with R2 values of 0.99 (Assay
Designs), 0.99 (in-house test), 0.98 (R&D), and 0.98
(IBL). As we suspected, the average values obtained for fl-
OPN levels were highly variable between assays using the
same group of breast cancer patient samples (Fig. 4). Con-
sistent with the prior comparison with the recombinant fl-
OPN standards (Fig. 3B), the IBL assay reflected the high-
est amount of fl-OPN, with an average of 1170 ng/ml,
which is 10-fold higher than the results from the other
three assays (Assay Designs 44.7 ng/ml, in house 4.3 ng/
ml, R&D 129 ng/ml). Surprisingly, however, the in-house
assay and the R&D assay, which were concordant in accu-
rately quantifying the recombinant standards (Fig. 3B),
were significantly different, with the quantification from
the R&D assay yielding values more than 10-fold higher
than the in-house ELISA. Also unexpected was the obser-
vation that the Assay Design test quantification was inter-
mediate between the in-house and the R&D assay, since it
showed consistently higher values than the other two
using the recombinant fl-OPN standards. There was heter-
ogeneity in OPN levels in the breast cancer patients (Fig.
4B). Similarly, quantification of plasma OPN in normal
healthy volunteers ranged between assays used. In gen-
eral, the relationship followed the breast cancer plasma
quantification, with the in house yielding the lowest
mean value, (1.2 ng/ml), followed by Assay Designs (32
ng/ml), R&D (53.9 ng/ml), and IBL (396.3 ng/ml). Using
all assays, the amount of circulating plasma OPN was
greater in the breast cancer samples compared to those
from normal volunteers (Assay Designs p = 0.025, R&D p
Table 2: Cancer patient study population.
Description n %
Histology
Invasive ductal 27 68
Invasive lobular 2 5
Other 11 28
Presenting stage of disease
I 5 13
II 15 38
III 8 20
IV 8 20
Unknown 4 10
Disease free interval
0 11 28
1–9 yrs 19 48
10+ yrs 9 23
Unknown 1 3
Hormone receptor status
ER+/PR+ 25 63
ER+/PR- 8 20
ER-/PR+ 1 3
ER-/PR- 3 8
Unknown 3 8
HER-2/neu overexpression
Positive 4 10
Negative 27 68
Unknown 9 23
Patient characteristics at time of breast cancer diagnosis (n = 40). 
Abbreviations: PR, progesterone receptor; ER, estrogen receptorPage 7 of 11
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difficult to accurately quantify in human blood, and com-
plicating factors need to be considered when evaluating
ELISA data quantifying fl-OPN.
Discussion
Biomarkers have been extensively studied across the
broad array of events that lead to the initial development
and ultimate progression of breast cancer. The present use
of breast cancer-related biomarkers is largely limited to: 1)
prognosis among those with a newly diagnosed cancer; 2)
assessment of an anticipated response to therapy and 3)
monitoring for those who are actively undergoing treat-
ment for known locally advanced or metastatic disease.
There is a widely recognized need for biomarkers that
could improve the clinician's ability to assess a woman's
risk for breast cancer as well as his/her ability to detect
breast cancer at it's earliest stages and to further identify
therapeutic targets [29,30].
A limited number of studies have tested the utility of fl-
OPN as a circulating breast cancer biomarker, using an
ELISA assay. In the first study [17], patients with meta-
static breast cancer disease were compared to control sub-
jects, and additionally, subdivided into groups with
increasing evidence of metastatic spread. The levels of
plasma osteopontin in the cohort with metastatic disease
was significantly increased compared to controls (p <
0.0001), and additionally, fl-OPN levels were further
increased in patients with three or more sites of metastatic
involvement compared to one or two metastatic sites.
Interestingly, follow up studies demonstrated that
increased plasma fl-OPN was associated with shorter sur-
vival of patients (p < 0.001).
That compelling study was validated by a prospective
study in metastatic breast cancer [20], in which 158 newly
diagnosed women with metastatic breast cancer were fol-
lowed every 3 to 12 weeks, during and after therapy until
death. Elevated baseline (newly diagnosed) fl-OPN levels
Quantification of circulating fl-OPN in plasma from breast cancer patients compared to normal healthy volunteersFigure 4
Quantification of circulating fl-OPN in plasma from breast cancer patients compared to normal healthy volun-
teers. A) Our newly developed ELISA (MAbs 2F10 and 1F11) were used to quantify plasma fl-OPN levels in fifty healthy volun-
teers (normal) versus forty patients with metastatic breast cancer (Stage IV). A significant increase was found in the cancer 
patient population. Graphed are means ± SEM. The same samples from normal volunteers or patients with metastatic breast 
cancer were quantified using the different fl-OPN assays, and graphed as means ± SEM. Note the different y-axis scales. The 
data are shown individually as well to reflect the range of values (B).Page 8 of 11
(page number not for citation purposes)
BMC Cancer 2008, 8:38 http://www.biomedcentral.com/1471-2407/8/38correlated with short survival (p = 0.02), and an increase
in fl-OPN levels during the course of the study had the
most prognostic value for poor survival (p = 0.0003). This
study demonstrated that sequential monitoring of fl-OPN
over time may provide data to indicate the course and
duration of the disease, and may assist in clinical therapy
decisions. Similar conclusions were drawn from a study
that examined OPN by immunostaining of tumors from
breast cancer patients [31].
There are several issues that are still outstanding with
regards to fl-OPN as a biomarker. First, Vordemark et al.
[21] highlighted the issues with variation between fl-OPN
ELISA test kits, and we also found a similar problem in
direct comparison of our newly developed ELISA with
commercially available kits. Therefore, an accurate quan-
tification of fl-OPN has not been independently vali-
dated, and based on our tests with known standard ranges
of fl-OPN, it appears that previous quantification of circu-
lating fl-OPN may have overestimated levels. It is impor-
tant to note differences between the ELISAs compared in
this study (Table 3). The IBL kit uses a polyclonal anti-
body against a peptide representing aa17–31 as the cap-
ture antibody, and a monoclonal antibody recognizing an
epitope on the right side of the thrombin cleavage site
(between aa168–169); the antigen was recombinant
human fl-OPN. The R&D Systems used recombinant fl-
OPN protein to generate a mouse monoclonal (unde-
fined) and a rabbit polyclonal (undefined) for the capture
and detection antibody, respectively. The Assay Designs
test has a capture antibody that is a monoclonal antibody
raised against a peptide (aa162–172) spanning a major
MMP site (aa166–167) and the thrombin cleavage site
(between aa168–169), and monoclonal antibody against
the C-terminal fragment as the detecting antibody.
Finally, our newly developed assay uses two monoclonal
antibodies raised against recombinant fl-OPN, one recog-
nizing the N-terminal fragment as the capture antibody,
and one recognizing the C-terminal fragment as the
detecting antibody.
Because the IBL test uses a polyclonal antibody as capture
antibody and the R&D Systems test has a polyclonal
detecting antibody, it is possible that there is more wide
recognition of epitopes including potential post-transla-
tional modifications. Differential post-translational mod-
ifications on OPN confer distinct biological activity [32-
34]. Because the Assay Designs capture antibody spans the
site of major proteolytic cleavage, there is a potential that
this assay can detect native C-terminal OPN fragment,
which is not detected by the other assays. This is of interest
given the recent demonstrations of C-terminal OPN frag-
ment influencing cell migration and invasion [35], in
some cases via an interaction with cyclophilin C [36].
Quantification of fl-OPN is also complicated by the
potential for the protein to bind to cell surfaces via
integrins, or to bind to circulating factors such as comple-
ment Factor H [37]. The consequences of protein-protein
interactions on fl-OPN detection in ELISA assays are not
known. Other tumor biomarkers, including prostate spe-
cific antigen, bind circulating proteins [38] that may affect
detection ability. Secondly, since detection of early stage
cancer is currently challenging, we hypothesized that if we
could develop a more sensitive fl-OPN assay, it may be
useful in detecting disease before advanced stages. Biolog-
ically, OPN expression has typically been shown to
increase with tumor progression, suggesting it as a theo-
retical biomarker of cancer progression [6,7,39].
Conclusion
We report the generation and characterization of novel
anti-OPN MAbs, and their utility in an ELISA for fl-OPN.
Table 3: Comparison of fl-OPN ELISA
IBL Assay Designs R&D Quantikine In house
Capture antibody Anti-human OPN (O-17), 
rabbit polyclonal IgG, 
recognizes N-terminal 
17IPVKQADSGSSEEKQ
Mouse monoclonal antibody 
to OPN, epitope includes 
162SVVYGLRSKSK
Mouse monoclonal antibody 
to OPN
Mouse monoclonal anti-
human OPN to N-fragment
Antigen Untagged rOPN/CHO cells 6x-C-terminal His tagged 
rOPN/mouse NS0 cells
6x-C-terminal His tagged 
rOPN/mouse NS0 cells
6x-C-terminal his tagged 
rOPN/E. coli
Detecting antibody Anti-human OPN (10A16), 
mouse IgG, Fab'-HRP, 
recognizes to the right of 
thrombin cleavag site 
170KSKKFRRPDIQYPDATD
E
Biotinylated monoclonal 
antibody to OPN. Epitope is 
located after the thrombin 
cleavage site,
Polyclonal anti-OPN 
conjugated to HRP
Mouse monoclonal anti-
human OPN to C-fragment
Detection and 
system
Full-length OPN, HRP-TMB Full-length OPN, biotin-
streptavidin-AP
Full-length OPN, HRP-TMB Full-length OPN, biotin-
streptavidin-HRP
Measur range 5–320 ng/ml 2–32 ng/ml 0.31–20 ng/ml 0.078–10 ng/ml
Sensitivy 5–320 ng/ml 0.110 ng/ml 0.011 ng/ml 0.014 ng/ml
Characteristics of each assay are indicated.Page 9 of 11
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ELISA kits, we find that our novel ELISA has increased sen-
sitivity to low levels of fl-OPN, and is accurate in quanti-
fying known OPN standards. Similar to previous studies,
our assay found elevated circulating fl-OPN levels in
patients with metastatic breast cancer. The discrepancies
between our results and previous quantification of plasma
fl-OPN in breast cancer patients are significant, and diffi-
cult to resolve. We propose that several factors, including
assay formats, OPN standards used, recognition of OPN
isoforms, fragments, or differences in specificity, may con-
tribute to the variations in fl-OPN amounts detected.
Thus, further refinements of these assays may provide bio-
logical information regarding specific subsets of OPN spe-
cies in cancer, whether generated by alternative splicing
[40] or post-translational modification, including prote-
olysis.
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